Kazuki Yoshida

List of Publications by Year
in descending order

90 papers	2,533 citations	218677 26 h-index	233421 45 g-index
98 all docs	98 docs citations	98 times ranked	3966 citing authors

#	Article	IF	Citations
1	Time-to-Furosemide Treatment and Mortality in Patients Hospitalized With Acute Heart Failure. Journal of the American College of Cardiology, 2017, 69, 3042-3051.	2.8	235
2	Active-comparator design and new-user design in observational studies. Nature Reviews Rheumatology, 2015, 11, 437-441.	8.0	225
3	Multimorbidity and rheumatic conditionsâ€"enhancing the concept of comorbidity. Nature Reviews Rheumatology, 2014, 10, 252-256.	8.0	103
4	Matching Weights to Simultaneously Compare Three Treatment Groups. Epidemiology, 2017, 28, 387-395.	2.7	97
5	Clinical Effectiveness of Tolvaptan in Patients With Acute Heart Failure and Renal Dysfunction. Journal of Cardiac Failure, 2016, 22, 423-432.	1.7	92
6	The impact of multimorbidity status on treatment response in rheumatoid arthritis patients initiating disease-modifying anti-rheumatic drugs. Rheumatology, 2015, 54, 2076-2084.	1.9	74
7	Delayed Denosumab Injections and Fracture Risk Among Patients With Osteoporosis. Annals of Internal Medicine, 2020, 173, 516-526.	3.9	65
8	Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan. Journal of Rheumatology, 2015, 42, 1439-1442.	2.0	63
9	Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. Seminars in Arthritis and Rheumatism, 2015, 45, 167-173.	3.4	58
10	Endothelial dysfunction measured by peripheral arterial tonometry predicts prognosis in patients with heart failure with preserved ejection fraction. International Journal of Cardiology, 2013, 168, 36-40.	1.7	55
11	Comparison of Denosumab and Bisphosphonates in Patients With Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 1753-1765.	3.6	55
12	Diet and Rheumatoid Arthritis Symptoms: Survey Results From a Rheumatoid Arthritis Registry. Arthritis Care and Research, 2017, 69, 1920-1925.	3.4	49
13	Biologic discontinuation studies: a systematic review of methods. Annals of the Rheumatic Diseases, 2014, 73, 595-599.	0.9	48
14	Infectious Diseaseâ€"Related Emergency Department Visits of Elderly Adults in the United States, 2011â€"2012. Journal of the American Geriatrics Society, 2016, 64, 31-36.	2.6	46
15	Carperitide Is Associated With Increased In-Hospital Mortality in Acute Heart Failure: A Propensity Scoreâ€"Matched Analysis. Journal of Cardiac Failure, 2015, 21, 859-864.	1.7	43
16	Sphingosylphosphorylcholine induces cytosolic Ca^{2+} elevation in endothelial cells in situ and causes endotheliumâ€dependent relaxation through nitric oxide production in bovine coronary artery. FEBS Letters, 1999, 457, 375-380.	2.8	42
17	Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registry. Annals of the Rheumatic Diseases, 2015, 74, 1150-1155.	0.9	41
18	Clinical Characteristics of Patients with Remitting Seronegative Symmetrical Synovitis with Pitting Edema Compared to Patients with Pure Polymyalgia Rheumatica. Journal of Rheumatology, 2012, 39, 148-153.	2.0	39

#	Article	IF	Citations
19	Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study. Journal of Rheumatology, 2015, 42, 1099-1104.	2.0	39
20	Confounding of the association between statins and Parkinson disease: systematic review and meta-analysis. Pharmacoepidemiology and Drug Safety, 2017, 26, 294-300.	1.9	39
21	Correlation of alpha angle between various radiographic projections and radial magnetic resonance imaging for cam deformity in femoral head–neck junction. Knee Surgery, Sports Traumatology, Arthroscopy, 2017, 25, 77-83.	4.2	38
22	Patient characteristics and predictors of mortality associated with pericardial decompression syndrome: a comprehensive analysis of published cases. European Heart Journal: Acute Cardiovascular Care, 2015, 4, 113-120.	1.0	37
23	Roles of Postdiagnosis Accumulation of Morbidities and Lifestyle Changes in Excess Total and Cause–Specific Mortality Risk in Rheumatoid Arthritis. Arthritis Care and Research, 2021, 73, 188-198.	3.4	36
24	Profile of infective endocarditis at a tertiary-care hospital in Japan over a 14-year period: characteristics, outcome and predictors for in-hospital mortality. International Journal of Infectious Diseases, 2015, 33, 62-66.	3.3	33
25	Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. Clinical Research in Cardiology, 2017, 106, 802-812.	3.3	30
26	Inverse probability weighted Cox model in multi-site studies without sharing individual-level data. Statistical Methods in Medical Research, 2020, 29, 1668-1681.	1.5	30
27	Risk of Hepatitis B Virus Reactivation in Patients With Inflammatory Arthritis Receiving Disease–Modifying Antirheumatic Drugs: A Systematic Review and Meta–Analysis. Arthritis Care and Research, 2018, 70, 724-731.	3.4	28
28	Comparison of Teriparatide and Denosumab in Patients Switching From Long-Term Bisphosphonate Use. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 5611-5620.	3.6	28
29	Clinical and Prognostic Values of ALBI Score in Patients With Acute Heart Failure. Heart Lung and Circulation, 2020, 29, 1328-1337.	0.4	28
30	Peripheral microvascular dysfunction predicts residual risk in coronary artery disease patients on statin therapy. Atherosclerosis, 2014, 232, 186-190.	0.8	27
31	Delayed Denosumab Injections and Bone Mineral Density Response: An Electronic Health Record-based Study. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 1435-1444.	3.6	26
32	Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry. Rheumatology, 2016, 55, 286-290.	1.9	25
33	Multinomial Extension of Propensity Score Trimming Methods: A Simulation Study. American Journal of Epidemiology, 2019, 188, 609-616.	3.4	25
34	Effects of Secondary Hyperparathyroidism Treatment on Improvement in Anemia: Results from the MBD-5D Study. PLoS ONE, 2016, 11, e0164865.	2.5	25
35	Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. Arthritis and Rheumatology, 2017, 69, 720-727.	5.6	24
36	Comparison of comorbidities and treatment between ankylosing spondylitis and non-radiographic axial spondyloarthritis in the United States. Rheumatology, 2019, 58, 2025-2030.	1.9	23

#	Article	IF	Citations
37	Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients. Seminars in Arthritis and Rheumatism, 2019, 49, 389-395.	3.4	22
38	An observational study of tocilizumab and TNF-Â inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology, 2011, 50, 2093-2099.	1.9	21
39	Clinical Effectiveness of Tolvaptan in Patients with Acute Decompensated Heart Failure and Renal Failure: Design and Rationale of the AQUAMARINE Study. Cardiovascular Drugs and Therapy, 2014, 28, 73-77.	2.6	20
40	Comparison of an administrative algorithm for SLE disease severity to clinical SLE Disease Activity Index scores. Rheumatology International, 2020, 40, 257-261.	3.0	20
41	A prospective study of dual-energy CT scanning, US and X-ray in acute calcium pyrophosphate crystal arthritis. Rheumatology, 2020, 59, 900-903.	1.9	19
42	Association of a Combination of Healthy Lifestyle Behaviors With Reduced Risk of Incident Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2022, 74, 274-283.	5.6	19
43	Passive Smoking Throughout the Life Course and the RiskÂof Incident Rheumatoid Arthritis in Adulthood AmongÂWomen. Arthritis and Rheumatology, 2021, 73, 2219-2228.	5.6	19
44	Prognostic impact of early treatment with tolvaptan in patients with acute heart failure and renal dysfunction. International Journal of Cardiology, 2016, 221, 188-193.	1.7	18
45	Recovery from hyponatremia in acute phase is associated with better in-hospital mortality rate in acute heart failure syndrome. Journal of Cardiology, 2016, 67, 406-411.	1.9	17
46	Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Nonselective NSAIDs in Taiwanese Patients With Rheumatoid Arthritis. Journal of the American Heart Association, 2017, 6, .	3.7	16
47	Initial disease severity, cardiovascular events and all-cause mortality among patients with systemic lupus erythematosus. Rheumatology, 2020, 59, 495-504.	1.9	16
48	Mortality trends in U.S. adults with septic shock, 2005-2011: a serial cross-sectional analysis of nationally-representative data. BMC Infectious Diseases, 2016, 16, 294.	2.9	15
49	Differences in clinical manifestations, treatment, and concordance rates with two major sets of criteria for BehÃ§etâ€™s syndrome for patients in the US and Japan: data from a large, three-center cohort study. Modern Rheumatology, 2013, 23, 547-553.	1.8	14
50	Incidence and Predictors of Biological Antirheumatic Drug Discontinuation Attempts among Patients with Rheumatoid Arthritis in Remission: A CORRONA and NinJa Collaborative Cohort Study. Journal of Rheumatology, 2015, 42, 2238-2246.	2.0	14
51	Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World. Journal of Rheumatology, 2019, 46, 896-903.	2.0	14
52	Improving rheumatoid arthritis comparative effectiveness research through causal inference principles: systematic review using a target trial emulation framework. Annals of the Rheumatic Diseases, 2020, 79, 883-890.	0.9	14
53	Classifying Pseudogout Using Machine Learning Approaches With Electronic Health Record Data. Arthritis Care and Research, 2021, 73, 442-448.	3.4	14
54	Effects of analgesics on bone mineral density: A longitudinal analysis of the prospective SWAN cohort with threeâ€group matching weights. Pharmacoepidemiology and Drug Safety, 2018, 27, 182-190.	1.9	13

#	Article	IF	Citations
55	Comparison of privacy‐protecting analytic and data‐sharing methods: A simulation study. Pharmacoepidemiology and Drug Safety, 2018, 27, 1034-1041.	1.9	13
56	Contribution of social factors to readmissions within 30 days after hospitalization for COPD exacerbation. BMC Pulmonary Medicine, 2020, 20, 107.	2.0	13
57	Prognostic importance of sodium level trajectory in acute heart failure. Heart and Vessels, 2017, 32, 1498-1505.	1.2	12
58	Prevalence and predictors for sustained remission in rheumatoid arthritis. PLoS ONE, 2019, 14, e0214981.	2.5	12
59	Atrial Fibrillation/flutter Hospitalizations among US Medicaid Recipients with and without Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 1359-1365.	2.0	12
60	Automated computed tomography quantification of fibrosis predicts prognosis in combined pulmonary fibrosis and emphysema in a real-world setting: a single-centre, retrospective study. Respiratory Research, 2020, 21, 275.	3.6	11
61	Clinical characteristics of non-radiographic versus radiographic axial spondyloarthritis in Asia and non-radiographic axial spondyloarthritis in other regions: results of the cross-sectional ASAS-COMOSPA study. RMD Open, 2021, 7, e001752.	3.8	11
62	Renal function on admission modifies prognostic impact of diuretics in acute heart failure: a propensity score matched and interaction analysis. Heart and Vessels, 2016, 31, 1980-1987.	1.2	10
63	Practice Pattern of Hepatitis B Testing in Rheumatoid Arthritis Patients: A Cross‐National Comparison Between the US and Taiwan. Arthritis Care and Research, 2018, 70, 30-38.	3.4	10
64	Outcomes of lupus and rheumatoid arthritis patients with primary dengue infection: A seven-year report from Brazil. Seminars in Arthritis and Rheumatism, 2018, 47, 749-755.	3.4	10
65	Inconsistent Treatment with Disease-modifying Antirheumatic Drugs: A Longitudinal Data Analysis. Journal of Rheumatology, 2014, 41, 2370-2378.	2.0	9
66	Versatility of the clone-censor-weight approach: response to â€œtrial emulation in the presence of immortal-time biasâ€. International Journal of Epidemiology, 2021, 50, 694-695.	1.9	9
67	Association of Healthy Lifestyle Behaviors and the Risk of Developing Rheumatoid Arthritis Among Women. Arthritis Care and Research, 2023, 75, 272-276.	3.4	9
68	Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine. Annals of the Rheumatic Diseases, 2022, 81, 1045-1048.	0.9	9
69	Acute Calcium Pyrophosphate Crystal Arthritis Flare Rate and Risk Factors for Recurrence. Journal of Rheumatology, 2020, 47, 1261-1266.	2.0	8
70	<scp>Time‐Varying</scp> Association of Rheumatoid Arthritis Disease Activity to Subsequent Cardiovascular Risk. ACR Open Rheumatology, 2022, 4, 587-595.	2.1	8
71	Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach. ACR Open Rheumatology, 2019, 1, 552-559.	2.1	7
72	Risk of Opioid Overdose Associated With Concomitant Use of Oxycodone and Selective Serotonin Reuptake Inhibitors. JAMA Network Open, 2022, 5, e220194.	5.9	7

#	Article	IF	Citations
73	Risk of cardiovascular events in patients having had acute calcium pyrophosphate crystal arthritis. Annals of the Rheumatic Diseases, 2022, 81, 1323-1329.	0.9	7
74	Clinical Features and Prognosis of Type 2 Myocardial Infarction in Vasospastic Angina. American Journal of Medicine, 2015, 128, 389-395.	1.5	6
75	A tool for empirical equipoise assessment in multigroup comparative effectiveness research. Pharmacoepidemiology and Drug Safety, 2019, 28, 934-941.	1.9	6
76	Use of data from multiple registries in studying biologic discontinuation: challenges and opportunities. Clinical and Experimental Rheumatology, 2013, 31, S28-32.	0.8	6
77	Smoking status and cause-specific discontinuation of tumour necrosis factor inhibitors in axial spondyloarthritis. Arthritis Research and Therapy, 2019, 21, 177.	3.5	5
78	Assessing improved risk prediction of rheumatoid arthritis by environmental, genetic, and metabolomic factors. Seminars in Arthritis and Rheumatism, 2021, 51, 1016-1022.	3.4	5
79	Unraveling the Role of Nonsteroidal Antiinflammatory Drugs in the Link Between Osteoarthritis and Cardiovascular Disease via Causal Mediation Analysis: A Guide to Interpretation. Arthritis and Rheumatology, 2019, 71, 1776-1779.	5.6	4
80	Safety of the anterior approach versus the lateral approach for chest tube insertion by residents treating spontaneous pneumothorax: a propensity score weighted analysis. General Thoracic and Cardiovascular Surgery, 2020, 68, 1425-1431.	0.9	4
81	Do rheumatologists know best? An outcomes study of inconsistent users of disease-modifying anti-rheumatic drugs. Seminars in Arthritis and Rheumatism, 2015, 44, 399-404.	3.4	3
82	Confirming Prior and Identifying Novel Correlates of Acute Calcium Pyrophosphate Crystal Arthritis. Arthritis Care and Research, 2023, 75, 283-288.	3.4	3
83	Causal mediation analysis of the relationship of canakinumab's effect against subsequent gout flares and highâ€sensitivity Câ€reactive protein in <scp>CANTOS</scp>. Arthritis Care and Research, 2021, , .	3.4	3
84	Response to: â€˜Biologic discontinuation studies: a systematic review of methodsâ€™ by van der Maas et al. Annals of the Rheumatic Diseases, 2014, 73, e5-e5.	0.9	2
85	Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study. PLoS ONE, 2019, 14, e0216399.	2.5	2
86	Prescribing Patterns of Hydroxychloroquine and Corticosteroids Among Lupus Patients After Newâ€onset Endâ€stage Renal Disease. Arthritis Care and Research, 2021, , .	3.4	2
87	Medications for gout and its comorbidities: mutual benefits?. Current Opinion in Rheumatology, 2021, 33, 145-154.	4.3	2
88	Dr. Yoshida, <i>et al</i> reply. Journal of Rheumatology, 2016, 43, 1253.2-1253.	2.0	0
89	188â€…Validation of an administrative algorithm to assess SLE disease severity. , 2019, , .		0
90	The relationship between 19â€year trends in medication use and changes in physical function among women in the midâ€life : A Study of Women 's Health Across the Nation pharmacoepidemiology study. Pharmacoepidemiology and Drug Safety, 2021, , .	1.9	0